Structural Biology And Drug Discovery Services
Protein X-Ray Crystallography, Protein NMR & Antibody Structures
SARomics Biostructures’ state of the art platform is built on many years of extensive expertise and experience in the fields of protein crystallization, X-ray crystallography and protein NMR spectroscopy. We offer a broad range of services which cover all aspects of structural biology:
• Gene-to-structure, FastLaneTM Standard & FastLaneTM Premium structures
• Protein NMR spectroscopy
• Protein expression, purification & crystallization
• Biophysical methods for protein characterization
• A catalogue of high purity crystallization grade recombinant proteins
The SARomics Biostructures team has also gathered many years of experience in biophysical characterization, crystallization and structure determination of antibody:antigen complexes. By combining NMR spectroscopy and X-ray crystallography, we can provide detailed characterization of biosimilars high order structure (HOS), including an analysis of its comparability with the originator antibody.
For details please follow the links below for respective services.
NEWS
March 2021
SARomics Biostructures' team contribute to an excellent Nature paper! Congratulations all involved!
November 2020
SARomics Biostructures together with its partner, Red Glead Discovery, join LundaGUARD, a consortium aimed at responding to present and future threats from infectious agents. Read more…
May 2020
Japanese and French presentation of SARomics Biostructures is now available!
Visit our blog, news archive or the Publications page for more company news and achievements!
Structural Biology Services
FastLane™ Premium
FastLane™ Standard
Gene-to-Structure
Industrial Enzymes
NMR Spectroscopy
Recombinant Proteins
Antibody-Antigen Complex Structure
Biosimilars Structure Characterization
ProPHECY™ Protein Optimization
Fragment Screening and Lead Generation
SARomics Biostructures’ integrated drug discovery services platform, which is run in close cooperation with Red Glead Discovery, combines key capabilities from a number of disciplines, which include:
• Weak Affinity Chromatography (WAC™)
• Nuclear Magnetic Resonance spectroscopy (NMR)
• Thermal Shift Assay (DSF)
• in silico screening and hit identification
• Biochemical & cell-based screening
Our proprietary weak affinity chromatography-based (WAC™) hit identification method has a proven track record of providing high quality lead fragments in projects which had often failed earlier screening efforts. Our drug discovery platform offers a variety of both pre-determined and custom drug discovery service packages.
Fragment-Based Drug Discovery Services
Weak-Affinity Chromatography
Fragment-Based Lead Generation
Structure-Based Drug Design
In silico Lead Discovery